You are here

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

Last updated on February 16, 2019

FOR MORE INFORMATION
Study Location
Landeskrankenhaus Bregenz
Bregenz, , A-6900 Austria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Renal Cell Carcinoma (mRCC)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patient 18 years of age and over

- Histologically confirmed diagnosis of advanced/metastatic renal carcinoma (clear cell
RCC as well as non-clear cell RCC) with measurable disease according to RECIST 1.1

- Patients being treated with Sutent in 1st line according to the European therapeutic
indication and/or being treated with Inlyta in 2nd line according to the European
approved therapeutic indication (except post cytokines)

- Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients being treated with cytokines or any other treatment outside of Sutent in 1st
line

- Patients receiving anti -tumor treatment beyond a second line

- Patients already under Sutent, already under Inlyta: enrolment must occur at the
beginning of each line of treatment (before or at the first follow up visit at the
latest)

NCT02184416
Pfizer
Recruiting
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now